A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

This study tests a new drug called JNJ-86974680 in patients with advanced non-small cell lung cancer (NSCLC). The trial has two parts: one for patients whose tumors have specific actionable mutations (like EGFR, ALK, ROS1, or BRAF) and who have already received all approved targeted treatments, and one for patients whose tumors have no targetable mutations. **You may be eligible if:** - You have confirmed stage IIIB-IV non-small cell lung cancer - Part 1: You have a known targetable mutation and have already tried all approved targeted therapies - Part 2: You have no targetable mutations - You have progressed on prior treatment **You may NOT be eligible if:** - You have active, uncontrolled brain metastases - You have certain heart, liver, or kidney problems - You are pregnant or breastfeeding - You have received drugs similar to JNJ-86974680 in the same class Talk to your doctor to see if this trial is right for you.